Molecure Past Earnings Performance
Past criteria checks 0/6
Molecure's earnings have been declining at an average annual rate of -44.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 31.2% per year.
Key information
-44.8%
Earnings growth rate
-42.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 29.4% |
| Revenue growth rate | -31.2% |
| Return on equity | -38.4% |
| Net Margin | -2,020.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?
Aug 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Apr 20We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate
Dec 01Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Jul 07Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Mar 10Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Aug 16OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem
Nov 04Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?
Feb 24Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?
Jan 02Revenue & Expenses Breakdown
How Molecure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2 | -31 | 26 | 0 |
| 30 Jun 24 | 2 | -30 | 27 | 0 |
| 31 Mar 24 | 2 | -29 | 27 | 0 |
| 31 Dec 23 | 4 | -28 | 28 | 0 |
| 30 Sep 23 | 9 | -45 | 45 | 0 |
| 30 Jun 23 | 8 | -42 | 41 | 0 |
| 31 Mar 23 | 8 | -39 | 38 | 0 |
| 31 Dec 22 | 8 | -36 | 35 | 0 |
| 30 Sep 22 | 2 | -16 | 16 | 0 |
| 30 Jun 22 | 2 | -16 | 15 | 0 |
| 31 Mar 22 | 2 | -15 | 14 | 0 |
| 31 Dec 21 | 1 | -14 | 12 | 0 |
| 30 Sep 21 | 124 | 63 | 14 | 0 |
| 30 Jun 21 | 124 | 64 | 14 | 0 |
| 31 Mar 21 | 125 | 67 | 12 | 0 |
| 31 Dec 20 | 125 | 68 | 12 | 0 |
| 30 Sep 20 | 2 | -3 | 5 | 0 |
| 30 Jun 20 | 2 | -3 | 5 | 0 |
| 31 Mar 20 | 2 | -4 | 5 | 0 |
| 31 Dec 19 | 2 | -4 | 6 | 0 |
| 30 Sep 19 | 2 | -5 | 6 | 0 |
| 30 Jun 19 | 2 | -5 | 6 | 0 |
| 31 Mar 19 | 1 | -5 | 6 | 0 |
| 31 Dec 18 | 1 | -4 | 5 | 0 |
| 30 Sep 18 | 1 | -4 | 5 | 0 |
| 30 Jun 18 | 2 | -4 | 4 | 0 |
| 31 Mar 18 | 2 | -2 | 4 | 0 |
| 31 Dec 17 | 1 | -2 | 3 | 0 |
| 30 Sep 17 | 1 | -3 | 2 | 0 |
| 30 Jun 17 | 1 | -3 | 2 | 0 |
| 31 Mar 17 | 1 | -3 | 2 | 0 |
| 31 Dec 16 | 1 | -2 | 2 | 0 |
| 31 Dec 15 | 1 | -1 | 1 | 0 |
Quality Earnings: MOC is currently unprofitable.
Growing Profit Margin: MOC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MOC is unprofitable, and losses have increased over the past 5 years at a rate of 44.8% per year.
Accelerating Growth: Unable to compare MOC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MOC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.9%).
Return on Equity
High ROE: MOC has a negative Return on Equity (-38.4%), as it is currently unprofitable.